N Bejanyan1, I Vlasova-St Louis2, H Mohei2, Q Cao3, N El Jurdi1, J E Wagner4, J S Miller1, C G Brunstein1. 1. Department of Medicine. University of Minnesota, Minneapolis, Minnesota. 2. Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota. 3. Biostatistics Core, Masonic Cancer Center. Adult and Pediatric Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota. 4. Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN.
Abstract
BACKGROUND: Rapid quantitative recovery of NK cells but slower recovery of T-cell subsets along with frequent viral infections are reported after umbilical cord blood (UCB) compared with matched sibling donor (MSD) hematopoietic cell transplantation (HCT). However, it remains unclear whether increased propensity for viral infections is also a result of slower recovery of virus-specific immunity after UCB as compared to MSD HCT. OBJECTIVES: We examined the differences in the function of virus-specific peripheral blood mononuclear cells (PBMC) after UCB (N=17) vs. MSD (N=9) using previously collected patient blood samples at various time points after HCT. METHODS: Interferon-gamma (IFN-γ) enzyme-linked immune absorbent spot (ELISpot) assay was used to quantify the PBMC frequencies that secrete IFN-γ in response to 11 immunopeptides from 5 common viruses. We included the patients who received the same reduced intensity conditioning regimen without ATG, no systemic glucocorticoids and had no relapse or acute/chronic graft-versus-host disease within 1 year after HCT. RESULTS: The CMV-reactive PBMC frequencies were higher in CMV seropositive vs. seronegative patients after HCT. Among CMV seropositive patients, the frequency of CMV-reactive PBMC was lower after UCB compared to MSD throughout one year of HCT. We observed no differences in virus-specific PBMC responses towards HHV6, EBV, BK, and adenovirus antigens between UCB and MSD. CONCLUSION: Our data demonstrate that the reconstitution of CMV-specific immunity is slower in CMV seropositive recipients of UCB vs. MSD HCT in contrast to other viruses which had similar recoveries. These study findings support implementation of more potent prophylactic strategies for preventing CMV reactivation in CMV seropositive patients receiving UCB HCT.
BACKGROUND: Rapid quantitative recovery of NK cells but slower recovery of T-cell subsets along with frequent viral infections are reported after umbilical cord blood (UCB) compared with matched sibling donor (MSD) hematopoietic cell transplantation (HCT). However, it remains unclear whether increased propensity for viral infections is also a result of slower recovery of virus-specific immunity after UCB as compared to MSD HCT. OBJECTIVES: We examined the differences in the function of virus-specific peripheral blood mononuclear cells (PBMC) after UCB (N=17) vs. MSD (N=9) using previously collected patient blood samples at various time points after HCT. METHODS: Interferon-gamma (IFN-γ) enzyme-linked immune absorbent spot (ELISpot) assay was used to quantify the PBMC frequencies that secrete IFN-γ in response to 11 immunopeptides from 5 common viruses. We included the patients who received the same reduced intensity conditioning regimen without ATG, no systemic glucocorticoids and had no relapse or acute/chronic graft-versus-host disease within 1 year after HCT. RESULTS: The CMV-reactive PBMC frequencies were higher in CMV seropositive vs. seronegative patients after HCT. Among CMV seropositive patients, the frequency of CMV-reactive PBMC was lower after UCB compared to MSD throughout one year of HCT. We observed no differences in virus-specific PBMC responses towards HHV6, EBV, BK, and adenovirus antigens between UCB and MSD. CONCLUSION: Our data demonstrate that the reconstitution of CMV-specific immunity is slower in CMV seropositive recipients of UCB vs. MSD HCT in contrast to other viruses which had similar recoveries. These study findings support implementation of more potent prophylactic strategies for preventing CMV reactivation in CMV seropositive patients receiving UCB HCT.
Authors: Xiao-Song He; Monia Draghi; Kutubuddin Mahmood; Tyson H Holmes; George W Kemble; Cornelia L Dekker; Ann M Arvin; Peter Parham; Harry B Greenberg Journal: J Clin Invest Date: 2004-12 Impact factor: 14.808
Authors: Prashant Sharma; Neel Gakhar; Jennifer MacDonald; Maheen Z Abidi; Esther Benamu; Valida Bajrovic; Enkhtsetseg Purev; Bradley M Haverkos; Jennifer Tobin; Jeff Kaiser; Stephanie Chase; Matthew Miller; Adriana Weinberg; Jonathan A Gutman Journal: Bone Marrow Transplant Date: 2019-10-29 Impact factor: 5.483
Authors: Rima M Saliba; Katayoun Rezvani; Ann Leen; Jeffrey Jorgensen; Nina Shah; Chitra Hosing; Simrit Parmar; Betul Oran; Amanda Olson; Gabriela Rondon; Julianne Chen; Charles Martinez; Amir Hamdi; Rohtesh S Mehta; Roy F Chemaly; Ila M Saunders; Catherine M Bollard; Elizabeth J Shpall Journal: Biol Blood Marrow Transplant Date: 2015-02-20 Impact factor: 5.742
Authors: Nelli Bejanyan; John Rogosheske; Todd DeFor; Aleksandr Lazaryan; Kelli Esbaum; Shernan Holtan; Mukta Arora; Margaret L MacMillan; Daniel Weisdorf; Pamala Jacobson; John Wagner; Claudio G Brunstein Journal: Biol Blood Marrow Transplant Date: 2015-02-03 Impact factor: 5.742
Authors: Patrick J Hanley; Conrad Russell Young Cruz; Barbara Savoldo; Ann M Leen; Maja Stanojevic; Mariam Khalil; William Decker; Jeffrey J Molldrem; Hao Liu; Adrian P Gee; Cliona M Rooney; Helen E Heslop; Gianpietro Dotti; Malcolm K Brenner; Elizabeth J Shpall; Catherine M Bollard Journal: Blood Date: 2009-05-14 Impact factor: 22.113
Authors: Sarah M Heston; Rebecca R Young; John S Tanaka; Kirsten Jenkins; Richard Vinesett; Frances M Saccoccio; Paul L Martin; Nelson J Chao; Matthew S Kelly Journal: Open Forum Infect Dis Date: 2021-12-16 Impact factor: 3.835